'Cd4 cell count' diaporamas de présentation

HIV-Associated Opportunistic Infections 2009

HIV-Associated Opportunistic Infections 2009. Robert D. Harrington, M.D. University of Washington. MMWR 1981. CD4 Count and Opportunistic Infections. CD4 Cell Count. Bacterial Pneumonia, TB, HSV, Cryptosporidiosis. 1,000. Thrush, lymphoma, KS. 500. 200. PCP. 100.

1.35k views • 83 slides

Initiation of antiretroviral treatment

821 views • 68 slides

Initiation of antiretroviral treatment

872 views • 68 slides

Initiation of antiretroviral treatment

838 views • 68 slides

Bienvenida

Bienvenida. Bienvenue. Welkom. Welcome. RETROVIRUS RESEARCH CENTER. CLINICAL, SOCIODEMOGRAPHIC AND IMMUNOLOGICAL PROFILE: BEFORE, DURING AND AFTER THE IMPLEMENTATION OF HAART THERAPY.

785 views • 58 slides

Safe Motherhood Programme

1.04k views • 56 slides

in + care Campaign Meet the Author December 12, 2012

in + care Campaign Meet the Author December 12, 2012. Ground Rules for Webinar Participation. Actively participate and write your questions into the chat area during the presentation(s) Do not put us on hold Mute your line if you are not speaking (press *6, to unmute your line press #6)

536 views • 37 slides

Thinking of Now and Tomorrow: Emerging Treatment Paradigms

Thinking of Now and Tomorrow: Emerging Treatment Paradigms. Pedro Cahn. Disclosures. Advisory boards : Merck, ViiV Healthcare Research funds : Abbvie , Merck, Richmond, ViiV Healthcare Speaker at educational activities : Abbvie , Gilead, Merck, ViiV Healthcare.

506 views • 32 slides

HCT Campaign and ARV Expansion programme

HCT Campaign and ARV Expansion programme. Business sectors leaders 29 March 2010. Goals. Implement the new treatment guidelines and Presidential mandates Train health workers on the new guidelines and policies Implement the HCT campaign strategy

414 views • 30 slides

OVERVIEW OF HIV VIROLOGY

OVERVIEW OF HIV VIROLOGY. BY EKEZIE F.M.C. INTRODUCTION AND VIROLOGY OF HIV. Hx: 1978 Unusual diseases among gays in USA 1980 31 deaths in USA 1981 PCP and Oropharyngeal candidiasis in 5 young homosexuals 1982 Dx linked to blood. AIDS first used in July 27

875 views • 21 slides

Selected and summarized by Douglas J. Ward, MD Dupont Circle Physicians Group Washington, DC

Highlights of the 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) September 14-17, 2003; Chicago, Illinois. Selected and summarized by Douglas J. Ward, MD Dupont Circle Physicians Group Washington, DC. Supported by an unrestricted educational grant from.

317 views • 19 slides

a ?10% non-inferiority margin for individual studies.

527 views • 13 slides

Introductory talk

Introductory talk. D Costagliola. Chapter 1. The current debate on abacavir. All or majority of patients antiretroviral-experienced at ABC initiation. All or majority of patients antiretroviral naive at ABC inclusion.

257 views • 13 slides

Introductory talk

Introductory talk. D Costagliola. Chapter 1. THE CURRENT DEBATE ON ABACAVIR. All or majority of patients antiretroviral-experienced at ABC initiation. All or majority of patients antiretroviral naive at ABC inclusion.

263 views • 13 slides

HIV Testing and Counseling and Male Circumcision Experiences from Zimbabwe

Scaling-up male circumcision programmes in the Eastern and Southern Africa Region Country update meeting. HIV Testing and Counseling and Male Circumcision Experiences from Zimbabwe. Karin Hatzold, MD, MPH Director HIV Services PSI Zimbabwe. Issues HTC/MC.

327 views • 12 slides

Comparison of NRTI combinations

Comparison of NRTI combinations. ZDV/3TC vs TDF + FTC Study 934 ABC/3TC vs TDF/FTC HEAT Study ACTG A5202 Study ASSERT Study TAF vs TDF Study 292-0102. Study 934: zidovudine/lamivudine fixed dose combination vs tenofovir + emtricitabine. Study 934. Design. Randomisation* 1 : 1

336 views • 8 slides

WEPDB0101

162 views • 3 slides

Poster # 873 *Sharon Nachman SUNY Stony Brook Stony Brook, NY sharon.nachman@stonybrook

CROI 2010 San Francisco, CA. . . Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth . Poster # 873 *Sharon Nachman SUNY Stony Brook Stony Brook, NY

216 views • 1 slides

Background

Background

60 views • 1 slides

Abstract

70 views • 1 slides